ECS Botanics is an Australian medicinal cannabis cultivator and manufacturer, focusing on the production of pharmaceutical grade cannabinoid products. The company utilizes innovative cultivation methodologies that are environmentally friendly and adopts regenerative and organic agricultural practices.

ECS Botanics

ECS Botanics is an Australian medicinal cannabis cultivator and manufacturer that focuses on producing pharmaceutical grade cannabinoid products.

ECS Botanics Holdings Ltd | 2,840 followers on LinkedIn. Cultivating and manufacturing to the highest pharmaceutical and commercial standards. | Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. ECS utilises progressive and innovative cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licenced by the Therapeutic Drug Administration to manufacture PIC/S GMP certified products, ECS has become a leading provider of high quality, affordable medicinal cannabis.

Managing Director at ECS Botanics Holdings Ltd

Nan-Maree Schoerie

NPD | Supply Chain | GMP | Quality | From the Emerald Triangle to Victoria AU

Susan Marr

Experienced Board Director | Public Health & Infectious Diseases Expert | VC, PE, PHI | Ex BCG | InDaily 40 under 40

Rachel Swift, DPhil (Oxon), FRSPH, FCHSM, GAICD, CHE

MSL Queensland at ECS Botanics

Jacqueline Carr

ECS Botanics Holdings Ltd

ECS Medical Advisory Board This is the first of 7 daily posts featuring the ECS’ medical Advisory Board. Dr Rupert Backhouse Rupert has been a GP in Mandurah WA for over 30 years. He has had an enduring passion for helping people with complex mental, physical and social problems. He has been a cannabis prescriber for over 5 years and seen the benefits of cannabis in many patients who have struggled to find relief of their symptoms from recommended interventions. In addition, Rupert has a very strong background in treatment of addiction problems and also seen the harms that can arise from cannabis and believes passionately in the safe and sensible use of cannabis as a medicine.

Introducing ECS-Botanics’ Medical Advisory Board With the launch of our B2C strategy, ECS-Botanics is proud to announce the creation of our Medical Advisory Board. This board plays a crucial role in guiding our patient-focused activities based on sound medical principles. Our advisors are experienced medical practitioners and thought leaders in medicinal cannabis medicine. They understand the importance of good clinical practice and the value of medicinal cannabis in supporting patient wellbeing. We deeply value the expert knowledge they bring to ECS-Botanics. Stay tuned for the first of seven daily posts featuring our esteemed Medical Advisory Board members.

ECS has delivered a strong quarter, driven by an exclusive license agreement with leading #cannabis breeding group #Terphogz , leadership appointments of Dr Rachel Swift and Nicholas Thomas, and a funding boost from the Victoria State Government (Victorian Government) through its 'Made in Victoria – Manufacturing Growth Program'. Managing Director, Nan-Maree Schoerie tells Cannabiz : “These initiatives coupled with greater production capabilities, increasing global demand, and a rapidly growing B2C business, strongly positions ECS for growth in the global market, and will ensure our high quality, #CertifiedOrganic medicinal cannabis is accessible by even more patients around the world." #ASXNews #SmallCaps #PotStocks #SmallCaps

We are thrilled to be exclusively partnering with #Terphogz to bring the award-winning #cannabis strain, ‘The Original Z’ (aka Zkittlez), to the Australian #medicinal market. This eight-year agreement will see ECS grow and distribute this iconic strain known for its unique terpene profile and therapeutic benefits across #Australia , #Germany , and #NewZealand . This is the first time any #Terphogz strain will be available outside #California and is a significant step in expanding our premium medicinal cannabis offerings. #MedicinalCannabis #NaturalMedicine #ASXNews #PotStocks

Interesting that Germany introduced a law that came into force on August 22, 2024 raising the limit for driving under the influence of cannabis to 3.5 ng/ml. https://lnkd.in/gRX8YnxX https://lnkd.in/gPbUr63N

Our #CEO , Nan-Maree Schoerie showcased our #leadership in Aussie grown, Certified Organic, #medicinalcannabis at the ASX Small and Mid-Cap Conference last week. Speaking with Proactive , Nan highlights our innovative, cost-effective cultivation methods, regenerative agriculture practices, and commitment to zero waste. Our certified #GMP facility in #Victoria is setting a new standard for environmentally friendly production, making premium medicinal cannabis accessible to patients globally. #ASXSM #MedicinalCannabis #NaturalMedicine #ASXNews #PotStocks #Organic

Great article from USA about our new partnership with Terphogz. https://lnkd.in/gKMiv3_h

About to launch Lime Haze… great name for this great sativa strain #medicinalcannabis #cannabisgenetics #inhouse #sativa

ECS is proud to announce the appointment of Nicholas Thomas as our new Chief Operating Officer (COO). Nicholas brings over 25 years of operational leadership experience in the Australian agricultural and horticultural sectors, with a proven track record in scaling operations and driving commercial success. His deep knowledge of end-to-end supply chain management and extensive expertise in Good Manufacturing Practice (GMP) will be pivotal as ECS continues to expand its international footprint and launch of new B2C product lines. Nicholas will oversee our daily operations, ensuring we optimise efficiencies and continue to deliver on our vision of leading the medicinal cannabis market globally. We are thrilled to have Nick on board and look forward to his contributions in driving operational excellence and sustainable growth. #leadership #cannabisindustry #b2c #b2b #ASXnews

We are thrilled to welcome Dr Rachel Swift, DPhil (Oxon), FRSPH, FCHSM, GAICD, CHE to the ECS Botanics Board as a Non-Executive Director. A Rhodes Scholar, Dr Swift brings nearly 20 years of experience in the healthcare sector, with a focus on health innovation, strategy, and governance. Her previous roles include senior positions at The Boston Consulting Group, and she currently serves on several boards within the healthcare and medical research fields. Dr. Swift's background includes expertise in public health, digital health, and medical research, which will be invaluable as ECS continues to grow within the medicinal cannabis industry. We look forward to the contributions of Dr. Swift as ECS continues to expand its leadership in the medicinal cannabis sector. #leadership #boardappointment #medicinalcannabis #ASXnews

Metric
Company Name	ECS Botanics
Symbol
MSH ID	COM:ECS-BOTANICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Pharmaceuticals
Country	AU
Stage
Employee Count	1
Website	ecs-botanics.com
LinkedIn	ecs-botanics-holdings-ltd
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	941
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ECS-

COM:ECS-BOTANICS

ECS Botanics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue